Generic Name: Crixivan
What is Crixivan?
Your doctor may have suggested this medication for conditions other than those listed in these drug information articles. If you have not discussed this with your doctor or are not sure why you are taking this medication, speak to your doctor. Do not stop taking this medication without consulting your doctor.
Many things can affect the dose of medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.
In order to get the most benefit from indinavir, it should be taken one hour before or 2 hours after a meal. Do not take indinavir with meals that are high in fat or calories, as this will reduce your body's ability to absorb the medication, which reduces its effectiveness.
Indinavir must be taken at 8 hour intervals to ensure there is enough medication in the bloodstream to be effective. It is important to drink extra fluids while taking this medication so that more urine is passed and to prevent kidney stones from developing. Discuss with your doctor how much fluid you should drink.
Caution should be used when oxybutynin is given in combination with inhibitors of CYP3A4, such as protease inhibitors. Monitor for adverse effects if these drugs are administered together. Oxycodone: Coadministration of indinavir, a potent CYP3A4 inhibitor, and oxycodone, a CYP3A4 substrate, may increase oxycodone plasma concentrations and increase or prolong related toxicities including potentially fatal respiratory depression. Paclitaxel: Indinavir inhibits cytochrome P450 3A4.
Although specific interactions have not been studied, Indinavir may reduce the metabolism of CYP3A4 substrates, such as paclitaxel, and caution is warranted with coadministration. Concentrations of indinavir may also increase. If concomitant use cannot be avoided, reduce the dose of palbociclib to 75 mg PO once daily and monitor for increased adverse reactions.
If indinavir is discontinued, increase the palbociclib dose after 3 to 5 half-lives of indinavir to the dose used before initiation of indinavir. Palbociclib is primarily metabolized by CYP3A4 and indinavir is a strong CYP3A4 inhibitor. Palbociclib is also a weak time-dependent inhibitor of CYP3A and indinavir is a sensitive CYP3A4 substrate. Indinavir is a strong CYP3A4 inhibitor and panobinostat is a CYP3A4 substrate.
Paricalcitol: Paricalcitol is partially metabolized by CYP3A4. Care should be taken when dosing paricalcitol with strong CYP3A4 inhibitors, such as protease inhibitors.
How should I take Crixivan?
This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site.
Gli altri due studi hanno comparato Crixivan assunto assieme a zidovudina e didanosina o lamivudina altri farmaci antivirali con Crixivan da solo e in combinazione con zidovudina e didanosina o lamivudina.
La ditta ha anche presentato i risultati di quattro studi tratti dalla letteratura scientifica che esaminavano gli effetti dell'assunzione di Crixivan in combinazione con ritonavir. Gli studi su Crixivan assunto con ritonavir hanno rivelato che la combinazione produceva livelli ematici di indinavir simili a quelli di Crixivan assunto senza ritonavir.
What should I avoid while taking Crixivan?
In addition, indinavir may inhibit the CYP metabolism of barbiturates, resulting in increased barbiturate concentrations. Appropriate dose adjustments necessary to ensure optimum levels of both anti-retroviral agent and the barbiturate are unknown. The CYP3A4 pathway is an important metabolic clearance route for codeine, and inhibition of this metabolic pathway by strong CYP3A4 inhibitors such as the anti-retroviral protease inhibitors may lead to elevated codeine concentrations that are available for conversion to morphine by CYP2D6.
Codeine should be used with caution in those patients receiving inhibitors of CYP3A4, or those who have increased endogenous CYP2D6 activity. Conduct regular patient observation, particularly during times of drug initiation, drug discontinuation, or dose adjustment. Monitor for altered pain response to codeine, and for excessive CNS sedation and respiratory depression. Perform dose adjustments as necessary to achieve stable patient response.
Hydrocodone is metabolized by CYP3A4.
Crixivan side effects
Note: Register pregnant patients exposed to indinavir by calling 800 258-4263. All Rights Reserved This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Advanced document searchThis is a summary of the European public assessment report EPAR for Crixivan.
It explains how the Committee for Medicinal Products for Human Use CHMP assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Crixivan. Crixivan is an antiviral medicine for treating adults infected with human immunodeficiency virus type 1 HIV 1a virus that causes acquired immune deficiency syndrome AIDS. Crixivan is used in combination with other antiviral medicines and contains the active substance indinavir.
Common Crixivan ide effects may include:
Crixivan can be taken with other liquids such as milk, juice, coffee or tea.
General Common side effects that have been reported by some indinavir users can include nausea, vomiting, abdominal or flank pain, headache, diarrhea, fatigue or weakness, and difficulty falling asleep.
OCD Brain Inflammation Tourette Syndrome vs.
The absence of warnings or other information for a given drug does not indicate that the drug or drug combination is safe, effective, or appropriate for all patients or all specific uses.
Methysergide: Coadministration of ergot alkaloids with potent inhibitors of CYP3A4, like anti-retroviral protease inhibitors is considered contraindicated due to the risk of acute ergot toxicity e. Midazolam: The use of oral midazolam and anti-retroviral protease inhibitors is contraindicated. Protease inhibitors have been shown to increase oral midazolam AUCs by up to 3-fold, resulting in clinically significant potentiation of sedation.
Lorazepam, oxazepam, or temazepam may be safer alternatives, as these benzodiazepines are not oxidatively metabolized.
Where can I get more information?
The plasma concentrations of both drugs may be elevated during concurrent use.
The appropriate doses for this combination, with respect to efficacy and safety, have not been established.